Jiangxi Fushine Pharmaceutical (300497) Fundamentals 2026 — Revenue Analysis | SniperIQ
Jiangxi Fushine Pharmaceutical (300497) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥8.8B, trading at ¥16.27 on the SHZ. This SniperIQ fundamentals page covers Jiangxi Fushine Pharmaceutical's valuation, profitability (net margin 0.3%), revenue (¥1.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Jiangxi Fushine Pharmaceutical's market cap?
Jiangxi Fushine Pharmaceutical (300497) has a market capitalization of approximately ¥8.8B, trading at ¥16.27 on the SHZ. Market cap moves with the live share price.
What is Jiangxi Fushine Pharmaceutical's P/E ratio?
Jiangxi Fushine Pharmaceutical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Jiangxi Fushine Pharmaceutical?
Jiangxi Fushine Pharmaceutical runs a net profit margin of 0.3%, a gross margin of 22.1%, and an operating margin of 1.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Jiangxi Fushine Pharmaceutical generate?
Jiangxi Fushine Pharmaceutical reported revenue of ¥1.2B for fiscal year 2025, with net income of -¥55M and earnings per share (EPS) of -0.1. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Jiangxi Fushine Pharmaceutical pay a dividend?
Jiangxi Fushine Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Jiangxi Fushine Pharmaceutical financially healthy?
Jiangxi Fushine Pharmaceutical carries a debt-to-equity ratio of 0.69x and a current ratio of 1.22x, with a market beta of 0.23. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Jiangxi Fushine Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Jiangxi Fushine Pharmaceutical (300497) the key facts are: market cap ¥8.8B, revenue ¥1.2B, 52-week range 9.4-24.18. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Jiangxi Fushine Pharmaceutical's full fundamentals live
Get Jiangxi Fushine Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.